Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 62.58 |
| Open | 62.81 |
| Bid | 62.71 x 40000 |
| Ask | 63.23 x 1800 |
| Day's range | 61.85 - 63.13 |
| 52-week range | 57.17 - 74.12 |
| Volume | |
| Avg. volume | 8,285,567 |
| Market cap | 79.122B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 17.62 |
| EPS (TTM) | 3.58 |
| Earnings date | 27 July 2022 - 01 Aug 2022 |
| Forward dividend & yield | 2.92 (4.63%) |
| Ex-dividend date | 14 June 2022 |
| 1y target est | 69.21 |
- Motley Fool
3 Top Dividend Stocks for Generating Passive Income
One great way to make passive income is to invest in dividend stocks. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings.
- Zacks
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
- Business Wire
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
FOSTER CITY, Calif., June 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
